The FDA has appointed Dr. Vinay Prasad, known for his outspoken criticism of pharmaceutical practices, as the new head of its biologics and vaccines division. This decision has sparked mixed reactions within the biotech industry. Prasad’s appointment comes amid concerns about the regulatory approach towards vaccines and biologics. Some observers worry that his leadership may lead to stricter evaluations, potentially affecting the approval process for new treatments. Biotech stocks have shown volatility following the announcement, reflecting uncertainty about the future regulatory environment under Prasad’s leadership. — new from statnews.com
